Platycodin D attenuates RA-stimulated endothelial cell proliferation, migration, and angiogenesis via CD146 modulation
Background
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation, leading to joint destruction. A key pathological feature is abnormal angiogenesis and proliferation of endothelial cells within the synovial membrane, contributing to disease progression and severity. Current therapies often have systemic side effects or limited efficacy in targeting the vascular component of RA. Identifying novel compounds that can specifically inhibit these pro-angiogenic and pro-proliferative processes in endothelial cells, potentially by modulating key surface markers like CD146, represents a promising therapeutic strategy to mitigate RA pathology.
Study Design
Researchers established an RA endothelial cell model by stimulating EA.hy926 cells with conditioned medium (CM) from TNF-α-activated MH7A synovial cells. Experimental groups included a normal control, the CM model, and treatment with Platycodin D (PD) at concentrations of 1.25, 2.5, and 5 mg/L for 24 hours. To investigate the mechanism, EA.hy926 cells were transduced with lentivirus for CD146 overexpression or knockdown. Cell proliferation was quantified using the CCK-8 assay, migration via wound-healing assay, and angiogenic capability through tube formation assays. CD146 expression levels were measured by Western blotting.
Results
CM stimulation significantly enhanced endothelial cell proliferation (P < 0.01) compared to the normal group. However, 24 hours of Platycodin D treatment notably decreased cell proliferation (P < 0.05). CM also improved cell migration ability, which was significantly diminished following PD treatment (P < 0.01). Furthermore, CM stimulation markedly increased tube formation capability, but this was significantly inhibited after 24 hours of PD treatment (P < 0.0001). CD146 expression levels were significantly elevated in the RA model group compared to the normal group. The study explored CD146 modulation as a potential mechanism for PD's effects, utilizing lentiviral overexpression and knockdown experiments to link PD's anti-angiogenic and anti-proliferative actions to this specific cell surface marker.
Platycodin D treatment significantly inhibited RA-stimulated endothelial cell tube formation by P < 0.0001, indicating potent anti-angiogenic effects.
Key Findings
- CM stimulation significantly enhanced endothelial cell proliferation (P < 0.01).
- Platycodin D treatment decreased RA-stimulated cell proliferation (P < 0.05).
- Platycodin D significantly diminished RA-stimulated cell migration (P < 0.01).
- Platycodin D significantly inhibited RA-stimulated tube formation (P < 0.0001).
- CD146 expression was significantly elevated in the RA model group.
Why It Matters
This in vitro study highlights Platycodin D as a promising compound for rheumatoid arthritis therapy by targeting the pathological angiogenesis and endothelial cell proliferation that drive disease progression. The finding that PD modulates CD146 provides a specific mechanistic pathway, suggesting that future drug development could focus on CD146 as a therapeutic target. For biohackers and clinicians, this indicates a potential natural compound with anti-inflammatory and anti-angiogenic properties, though it's currently far from a usable clinical protocol. Further preclinical and clinical studies are needed to validate these findings in vivo and determine optimal dosing and delivery methods for human application. This research expands the understanding of natural product mechanisms in inflammation.
platycodin d
rheumatoid arthritis
angiogenesis
cd146
in vitro
endothelial cells